BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. announced it has engaged Charles River Associates (CRA) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand planning for its drug candidate, Bria-IMT. CRA will evaluate epidemiology, pricing, prescriber dynamics, and market access potential in metastatic breast cancer, while Kaleio will focus on brand strategies. Bria-IMT is currently undergoing a pivotal Phase 3 study, and these engagements are a proactive step towards potential future commercialization.

BriaCell Therapeutics Corp.'s subsidiary, BriaPro Therapeutics Corp., filed its unaudited interim consolidated financial statements for the three and nine months ended April 30, 2026. A key development was BriaPro's acquisition of an exclusive license for Soluble CD80 (sCD80) for cancer treatment from BriaCell, valued at $846,532, paid in shares. BriaPro reported a net loss of $712,236 for the nine-month period and received a $300,000 advance from a $3,000,000 credit facility from BriaCell to fund sCD80 research and development.

BriaCell Therapeutics Corp. has signed a Memorandum of Understanding (MoU) with Uneedle, a microneedle-based drug-delivery device company. This non-binding agreement supports the continued use and commercial readiness of Uneedle's proprietary microneedle technology for the intradermal administration of BriaCell's lead Phase 3 clinical candidate, Bria-IMT, for metastatic breast cancer. The technology is already being used in BriaCell's ongoing pivotal Phase 3 study and aims to provide faster, more convenient, and patient-friendly treatment.

BriaCell Therapeutics reported a net loss of $(7.24) million for the three months and $(22.81) million for the nine months ended April 30, 2026, with an accumulated deficit of $(134.34) million. The company issued a going concern warning due to sustained operating losses but successfully raised approximately $30.0 million in gross proceeds from a public offering in January 2026. BriaCell also increased its ownership in BC Therapeutics to 69.04% and in BriaPro to approximately 78% following a transaction.

BriaCell Therapeutics Corp. closed a best efforts offering on June 2, 2026, selling an aggregate of 1,449,300 common shares at an offering price of $3.25 per share. The offering resulted in gross proceeds of $4.71 million, which the company intends to use for working capital, general corporate purposes, and advancing business objectives. ThinkEquity LLC acted as the placement agent, receiving a 7.5% cash fee and warrants to purchase 72,465 common shares.

BriaCell Therapeutics Corp. announced the pricing of a best-efforts offering of 1,449,300 common shares at $3.25 per share. The offering is expected to generate approximately $4.7 million in gross proceeds and is anticipated to close on June 2, 2026. The company intends to use the net proceeds for working capital requirements, general corporate purposes, and the advancement of business objectives.

BriaCell Therapeutics announced that its independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation for the continuation of the pivotal Phase 3 Bria-ABC study. The DSMB found no safety concerns and recommended the study proceed without modifications. This study, which evaluates Bria-IMT plus an immune checkpoint inhibitor for patients with metastatic breast cancer, is being conducted under FDA Fast Track Designation, underscoring the significant unmet medical need.

BriaCell Therapeutics announced positive clinical data from its Bria-IMT studies, presented at the 2026 ASCO Annual Meeting. The final Phase 2 data showed a median overall survival of 16.6 months with the Phase 3 formulation, with 52% of patients surviving at 12 months and 26% at 24 months. Additionally, the ongoing pivotal Phase 3 study demonstrated positive Quality of Life data, indicating preserved QOL and meaningful benefits without significant toxicity for heavily pre-treated metastatic breast cancer patients. Biomarker analyses from the Phase 3 study also confirmed predictors of anti-cancer response, with 65% of patients showing stable or dropping Cancer-Associated Macrophage-Like cells correlating with better progression-free survival.

BriaCell Therapeutics Corp. announced its expansion into women's health, focusing on ovarian cancer with its new personalized immunotherapy candidate, Bria-OVA+. This strategic move follows encouraging efficacy and tolerability data from the company's Phase 2 study in metastatic breast cancer. Bria-OVA+ is designed as a next-generation, off-the-shelf, cell-based immunotherapy to address the significant unmet medical need in ovarian cancer, which remains the deadliest gynecologic cancer. The company has initiated development activities for Bria-OVA+ after licensing necessary cell lines.

BriaCell Therapeutics has completed manufacturing clinical supplies of Bria-PROS+, its next-generation personalized off-the-shelf immunotherapy for prostate cancer. The company plans to initiate a Phase 1/2a clinical study for Bria-PROS+ in the coming months, supported by a $2 million non-dilutive grant from the US National Cancer Institute. Preclinical data demonstrated that Bria-PROS+ activated both adaptive and innate immunity, supporting its further clinical evaluation. This candidate builds on the Bria-OTS+ platform, which also underpins Bria-BRES+, a breast cancer immunotherapy that recently received FDA IND clearance.